SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference

JERSEY CITY, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ: SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.

A live webcast will be available on the investors section of the Company's website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXISSCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.

CONTACT:

Media Relations
Blair Atkinson
MacDougall Biomedical Communications
Tel: 781.235.3060
[email protected]

Investor Relations
Susan Kim
Argot Partners
Tel: 212.203.4433
[email protected]

You May Also Be Interested In

• SCYNEXIS (SCYX) PT Raised to $33 at Guggenheim
• HH Group Acquires Strategic Washington, D.C. Student Housing Investment Near George Washington University, Expanding National Portfolio
• Carbon Capture Canada Returns Amid Growing Investment and Momentum in Canada's Carbon Capture, Utilization and Storage Sector